Results 61 to 70 of about 63,084 (302)

Comorbidities of patients in tiotropium clinical trials : comparison with observational studies of patients with chronic obstructive pulmonary disease [PDF]

open access: yes, 2015
Acknowledgments The authors are fully responsible for all content and editorial decisions made, were involved at all stages of manuscript development, and have approved the final version for publication.
Celli, Bartolome   +5 more
core   +1 more source

A retrospective cohort study evaluating the growth and clinical outcomes of preterm and term infants with cystic fibrosis during the first 11 years of life

open access: yesJPGN Reports, EarlyView.
Abstract Objectives Infants with cystic fibrosis (iwCF) have lower birth weights than others. That influences nutritional and pulmonary outcomes. It was reported that 86.0% of iwCF were born full‐term and 14.0% preterm. Data on the role of gestational age in growth and clinical outcomes of people with cystic fibrosis (pwCF) is limited.
Hebah Reda   +3 more
wiley   +1 more source

Genome-Wide Association Study of Bronchodilator Drug Response (BDR) in Minority Children with Asthma Provides Insights into Its Genetic Risk Factors [PDF]

open access: gold, 2021
Jin Hui Joo   +12 more
openalex   +1 more source

Oxymatrine Inhibits Epithelial‐Mesenchymal Transition to Alleviate Airway Remodeling in Chronic Obstructive Pulmonary Disease by Suppressing the TGF‐β1/Smad Pathway

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study explored the therapeutic efficacy of oxymatrine (OMT, C15H24N2O2) in a murine model of cigarette smoke (CS)‐induced chronic obstructive pulmonary disease (COPD) and elucidated its underlying mechanisms. A COPD model was established in mice through prolonged exposure to CS, followed by intraperitoneal administration of OMT (50 mg/kg)
Shuang Zhou, Ju‐Xiang Zhu, Jing Li
wiley   +1 more source

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD

open access: yesInternational Journal of COPD, 2019
James F Donohue,1 Donald A Mahler,2,3 Sanjay Sethi4 1Pulmonary Medicine, UNC School of Medicine, Chapel Hill, NC, USA; 2Geisel School of Medicine at Dartmouth, Hanover, NH, USA; 3Director of Respiratory Services, Valley Regional Hospital, Claremont, NH ...
Donohue JF, Mahler DA, Sethi S
doaj  

Salbutamol Transport and Deposition in the Upper and Lower Airway with Different Devices in Cats: A Computational Fluid Dynamics Approach

open access: yesAnimals, 2021
Pressurized metered-dose inhalers (pMDI) with or without spacers are commonly used for the treatment of feline inflammatory airway disease. During traditional airways treatments, a substantial amount of drugs are wasted upstream of their target. To study
Rocio Fernández-Parra   +3 more
doaj   +1 more source

Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis [PDF]

open access: yes, 2019
BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4 and IL-13 signaling, key drivers of type 2 inflammation.
Castro, Mario, et al,, Maspero, Jorge F
core   +1 more source

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events [PDF]

open access: yes, 2010
Background An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in comparison with placebo in previous Cochrane reviews.
Aalbers   +27 more
core   +2 more sources

Potential Biomarkers for Disease Stratification and Prognosis Prediction in Pediatric Asthma: LCN2, sST2 and FGF21

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Pediatric asthma is a common chronic airway inflammatory disease, where accurate assessment of disease severity and prognosis prediction is crucial for treatment decisions. Currently, there is a lack of precise and effective biomarkers.
Xu Yang   +5 more
wiley   +1 more source

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD : a systematic review and meta-analysis [PDF]

open access: yes, 2017
Acknowledgments The meta-analysis work was performed by Guruprasad Rao KS and Sharanbasappa Durg of Molecular Connections (P) Ltd, Bangalore, India, under the guidance of the manuscript authors and Novartis Pharma AG (Basel, Switzerland). Medical writing
Altman, Pablo   +8 more
core   +2 more sources

Home - About - Disclaimer - Privacy